IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from…
Tag: 2018
ObsEva SA to Participate in November Investor Conferences
Geneva, Switzerland and Boston, MA – November 7, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018
(GLOBE NEWSWIRE via COMTEX) –Geneva, Switzerland and Boston, MA –October 31, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN),…
Q3 2018 ObsEva SA Earnings Conference Call
Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to…
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate…
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA – October 5, 2018– ObsEva SA (NASDAQ: OBSV / SIX:…
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety…
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain
Linzagolix overall efficacy and safety maintained or improved at week 24 Linzagolix 75mg once daily showed no clinically significant impact…
Investora 6th Swiss Small and Mid-Cap Conference
Date & Time: 27 Sep 2018 4:15 p.m. CEST / 10:15am EDT Location: Zurich, Switzerland
BioCentury’s 25th Annual NewsMakers in the Biotech Industry Conference
Click here for webcast Date & Time: Friday, September 7, 2018 11:30 a.m. ET Location: New York